Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.

@article{Barkin2003AlphablockerTC,
  title={Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.},
  author={Jodie A. Barkin and Miguel Julio Machado Guimar{\~a}es and G{\"u}nther Heinz Jacobi and Dmitry U. Pushkar and Simone Taylor and Oncko B. van Vierssen Trip},
  journal={European urology},
  year={2003},
  volume={44 4},
  pages={
          461-6
        }
}
OBJECTIVES The Symptom Management After Reducing Therapy (SMART-1) study examined the combination of the dual action 5alpha-reductase inhibitor (5ARI) dutasteride, and alpha(1)-blocker tamsulosin, followed by withdrawal of tamsulosin in men with symptomatic BPH. METHODS 327 BPH patients were randomised to 0.5mg dutasteride and 0.4 mg tamsulosin for 36 weeks (DT36) or 0.5 mg dutasteride and 0.4 mg tamsulosin for 24 weeks followed by dutasteride and tamsulosin matched placebo for the remaining… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 70 CITATIONS

Similar Papers

Loading similar papers…